Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Full text not available from this repository.

Abstract

PURPOSE The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia. With all patients off treatment for least three years, we report a detailed analysis of minimal residual disease (MRD) kinetics and long-term outcome of patients treated in the CLL14 study. PATIENTS AND METHOD Patients were randomly assigned to receive six cycles of obinutuzumab with 12 cycles of venetoclax or 12 cycles of chlorambucil (CIb-Obi). Progression-free survival (PFS) was the primary end point. Key secondary end points included rates of undetectable MRD and overall survival. To analyze MRD kinetics, a population-based growth model with nonlinear mixed effects approach was developed. RESULTS Of 432 patients, 216 were assigned to Ven-Obi and 216 to CIb-Obi. Three months after treatment completion, 40% of patients in the Ven-Obi arm (7% in the CIb-Obi arm) had undetectable MRD levels < 10(-6) by next-generation sequencing in peripheral blood. Median MRD doubling time was longer after Ven-Obi than CIb-Obi therapy (median 80 v 69 days). At a median follow-up of 52.4 months, a sustained significant PFS improvement was observed in the Ven-Obi arm compared with CIb-Obi (median not reached v 36.4 months; hazard ratio 0.33; 95% CI, 0.25 to 0.45; P < .0001). The estimated 4-year PFS rate was 74.0% in the Ven-Obi and 35.4% in the CIb-Obi arm. No difference in overall survival was observed (hazard ratio 0.85; 95% CI, 0.54 to 1.35; P = .49). No new safety signals occurred. CONCLUSION Appearance of MRD after Ven-Obi is significantly slower than that after CIb-Obi with more effective MRD reduction. These findings translate into a superior long-term efficacy with the majority of Ven-Obi-treated patients remaining in remission. (C) 2021 by American Society of Clinical Oncology

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Al-Sawaf, OthmanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Zhang, CanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lu, TongUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Liao, Michael Z.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Panchal, AneshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Robrecht, SandraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ching, TraversUNSPECIFIEDorcid.org/0000-0002-5577-3516UNSPECIFIED
Tandon, ManeeshUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fink, Anna-MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Tausch, EugenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schneider, ChristofUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ritgen, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boettcher, SebastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kreuzer, Karl-AntonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Chyla, BrendaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Miles, DaleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wendtner, Clemens-MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eichhorst, BarbaraUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, StephanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jiang, YanwenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Fischer, KirstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-602513
DOI: 10.1200/JCO.21.01181
Journal or Publication Title: J. Clin. Oncol.
Volume: 39
Number: 36
Page Range: S. 4049 - 4062
Date: 2021
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Place of Publication: PHILADELPHIA
ISSN: 1527-7755
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC LYMPHOCYTIC-LEUKEMIA; QUANTIFICATION; CHLORAMBUCIL; GUIDELINESMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60251

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item